Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 11:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pharmacokinetics of Metformin Clear all
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Assess the Effect of ABBV-722 on Midazolam, Digoxin, Pitavastatin, Metformin, and Sitagliptin Drug Levels in Healthy Adults.

NCT07567781
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ABBV-722, Midazolam, Metformin, Digoxin, Pitavastatin, Sitagliptin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jun 10, 2026, 11:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of a Fixed Dose Combination of Canagliflozin/Metformin Coadministered With Food

NCT02039258
View directory record Official record
Conditions
Healthy Volunteers
Interventions
CANA/MET XR FDC
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 13, 2014 · Synced Jun 10, 2026, 11:19 PM EDT
Completed Phase 1 Interventional

To Evaluate Safety and Tolerability After Multiple Oral Doses of AZD1656 in Type 2 Diabetes Patients on Top of Metformin

NCT00774553
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
AZD1656, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
30 Years to 75 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 14, 2010 · Synced Jun 10, 2026, 11:19 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus

NCT02000700
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Canagliflozin 100 mg, Canagliflozin 50 mg, Canagliflozin 300 mg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
10 Years to 17 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
13
States / cities
Little Rock, Arkansas • Los Angeles, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Jun 10, 2026, 11:19 PM EDT
Completed Phase 1 Interventional

Single Cohort 4-period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With Ranolazine

NCT01546597
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Metformin, Ranolazine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
30 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 10, 2012 · Synced Jun 10, 2026, 11:19 PM EDT
Terminated Phase 1 Interventional Results available

Study of Saxagliptin, 5-Hydroxy Saxagliptin, and Metformin Concentrations/Levels in Pediatric Subjects With T2DM

NCT01525225
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Metformin immediate release (IR), Saxagliptin, Metformin IR, Saxagliptin/Metformin XR FDC, Metformin XR
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
10 Years to 17 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
7
States / cities
Little Rock, Arkansas • Los Angeles, California • Louisville, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2015 · Synced Jun 10, 2026, 11:19 PM EDT
Completed Phase 1 Interventional

A Clinical Trial Study to Determine the Effect of an Investigational Drug (SEP-363856) Has on the Way That the Drug Metformin Travels Through the Body in People With Schizophrenia.

NCT04865835
View directory record Official record
Conditions
Schizophrenia
Interventions
placebo, SEP-363856, metformin
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Oakland Park, Florida • Marlton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Jun 10, 2026, 11:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of the Effect of Abemaciclib on Metformin and Iohexol in Healthy Participants

NCT02884089
View directory record Official record
Conditions
Healthy
Interventions
Abemaciclib, Metformin, Iohexol, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 3, 2019 · Synced Jun 10, 2026, 11:19 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both

NCT05260021
View directory record Official record
Conditions
Type2 Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, T2D, T2DM (Type 2 Diabetes Mellitus), Glucose Metabolism Disorders, Endocrine System Diseases, Metabolic Disease
Interventions
Tirzepatide Dose 1, Tirzepatide Dose 2, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
10 Years to 18 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
13
States / cities
Los Angeles, California • Sacramento, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Jun 10, 2026, 11:19 PM EDT
Completed Phase 1 Interventional

Single Dose Pharmacokinetics of Repaglinide, Metformin and Combination Tablet in Fed Healthy Volunteers

NCT01490658
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
repaglinide, metformin, repaglinide and metformin combination tablet
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 45 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Jun 10, 2026, 11:19 PM EDT
Recruiting Phase 2 Interventional

The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action

NCT05414409
View directory record Official record
Conditions
Type 1 Diabetes, Obesity
Interventions
Metformin
Drug
Lead sponsor
Heba M. Ismail
Other
Eligibility
11 Years to 18 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 24, 2025 · Synced Jun 10, 2026, 11:19 PM EDT
Completed Phase 1 Interventional

Single Ascending Dose Study of BMS-820132 in Patients With Type 2 Diabetes

NCT01105429
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
BMS-820132, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
3
States / cities
Chula Vista, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 8, 2011 · Synced Jun 10, 2026, 11:19 PM EDT
Completed Phase 2 Interventional

A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.

NCT00423501
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
Placebo, taspoglutide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
10
States / cities
Washington D.C., District of Columbia • Woodstock, Georgia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Jun 10, 2026, 11:19 PM EDT
Completed Phase 2 Interventional Results available

BI 10773 add-on to Metformin in Patients With Type 2 Diabetes

NCT00749190
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
BI 10773, placebo, sitagliptin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 79 Years
Enrollment
495 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
19
States / cities
Chula Vista, California • Mission Viejo, California • Pasadena, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2014 · Synced Jun 10, 2026, 11:19 PM EDT
Terminated Phase 2 Interventional

Efficacy and Safety Study of JTT-654 in Type 2 Diabetic Patients

NCT00997152
View directory record Official record
Conditions
Type II Diabetes Mellitus
Interventions
JTT-654, JTT-654 Placebo
Drug
Lead sponsor
Akros Pharma Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
42
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2013 · Synced Jun 10, 2026, 11:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effect of Povorcitinib on Digoxin, Rosuvastatin, and Metformin Pharmacokinetics and the Effect of Probenecid on Povorcitinib Pharmacokinetics When Administered Orally to Healthy Adult Participants

NCT06416800
View directory record Official record
Conditions
Healthy Participants
Interventions
Digoxin, Rosuvastatin, Metformin, Povorcitinib, Probenecid
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Jun 10, 2026, 11:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Multiple Dose Pharmacokinetics of Canagliflozin/Metformin 150/1,000 mg Fixed Dose Combination

NCT02039245
View directory record Official record
Conditions
Healthy Volunteers
Interventions
CANA/MET XR FDC
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 1, 2014 · Synced Jun 10, 2026, 11:19 PM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Patients With Type 2 Diabetes

NCT00605475
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Canakinumab, Placebo, Metformin
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 70 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
6
States / cities
Little Rock, Arkansas • Miami, Florida • MD, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2012 · Synced Jun 10, 2026, 11:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Randomized, Placebo-controlled Study to Evaluate Effects of E5555 on Renal Function Parameters and OCT2 Activity

NCT01241669
View directory record Official record
Conditions
Healthy Subjects
Interventions
E5555
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2010
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 10, 2014 · Synced Jun 10, 2026, 11:19 PM EDT
Completed Phase 1 Interventional

Multiple Ascending Dose Study of BMS-820132 in Patients With Type 2 Diabetes

NCT01290575
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Placebo, BMS-820132
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
5
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2012 · Synced Jun 10, 2026, 11:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Clinical Study of Calderasib (MK-1084) With Rosuvastatin and Metformin in Healthy People (MK-1084-016)

NCT07222098
View directory record Official record
Conditions
Healthy
Interventions
Rosuvastatin, Metformin, Calderasib
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
19 Years to 60 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jun 10, 2026, 11:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Belzutifan (MK-6482) and Metformin in Healthy Adult Participants (MK-6482-039)

NCT07121959
View directory record Official record
Conditions
Healthy
Interventions
Metformin, Belzutifan
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Jun 10, 2026, 11:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Explore Pharmacokinetic Interaction Between Rilpivirine and Metformin in Healthy Participants

NCT01719614
View directory record Official record
Conditions
Healthy Participants
Interventions
Metformin, Rilpivirine
Drug
Lead sponsor
Janssen R&D Ireland
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 5, 2014 · Synced Jun 10, 2026, 11:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of Metformin

NCT01884558
View directory record Official record
Conditions
Pharmacokinetics of Isavuconazole, Pharmacokinetics of Metformin, Healthy Subjects
Interventions
isavuconazole, metformin
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2013 · Synced Jun 10, 2026, 11:19 PM EDT